Search results for "Placebo"

showing 10 items of 704 documents

Effects of bovine colostrum supplementation on serum IGF-I, IgG, hormone, and saliva IgA during training.

1997

Mero, Antti, Heidi Miikkulainen, Jarmo Riski, Raimo Pakkanen, Jouni Aalto, and Timo Takala. Effects of bovine colostrum supplementation on serum IGF-I, IgG, hormone, and saliva IgA during training. J. Appl. Physiol.83(4): 1144–1151, 1997.—The purpose of this study was to examine the effects of bovine colostrum supplementation (Bioenervi) on serum insulin-like growth factor I (IGF-I), immunoglobulin G, hormone, and amino acid and saliva immunoglobulin A concentrations during a strength and speed training period. Nine male sprinters and jumpers underwent three randomized experimental training treatments of 8 days separated by 13 days. The only difference in the treatments was the drink of 125…

Immunoglobulin AAdultMalemedicine.medical_specialtySalivaPhysiologymedicine.medical_treatmentPlaceboImmunoglobulin GDouble-Blind MethodPhysiology (medical)Internal medicineMedicineAnimalsHumansNutritional Physiological PhenomenaInsulin-Like Growth Factor ISalivaCross-Over Studiesbiologybusiness.industryInsulinColostrumTrack and FieldCrossover studyHormonesImmunoglobulin AEndocrinologyPhysical FitnessImmunoglobulin Gbiology.proteinColostrumCattlebusinessHormoneJournal of applied physiology (Bethesda, Md. : 1985)
researchProduct

Antihyperalgesic and analgesic properties of the N-methyl-d-aspartate (NMDA) receptor antagonist neramexane in a human surrogate model of neurogenic …

2006

Abstract NMDA-receptors are a major target in the prevention and treatment of hyperalgesic pain states in neuropathic pain. However, previous studies revealed equivocal results depending on study design and efficacy parameters. We tested the analgesic (generalized reduction of generation and processing of nociceptive signalling) and anti-hyperalgesic (prevention of central sensitization) properties of the NMDA-receptor antagonist neramexane and the potassium channel opener flupirtine in the intradermal capsaicin injection model. Furthermore, we tested the effect on pain summation (wind up). Eighteen healthy subjects received either a single dose of neramexane (40 mg p.o.), flupirtine (100 m…

Injections IntradermalAnalgesicAminopyridinesPainCyclopentanesPharmacologyPlaceboReceptors N-Methyl-D-AspartateDouble-Blind MethodPhysical StimulationHumansMedicineAnalgesicsCross-Over StudiesDose-Response Relationship Drugbusiness.industryNeramexaneTreatment OutcomeAnesthesiology and Pain MedicineAllodyniaNociceptionHyperalgesiaAnesthesiaNeuropathic painHyperalgesiaCapsaicinNervous System Diseasesmedicine.symptomFlupirtinebusinessmedicine.drugEuropean Journal of Pain
researchProduct

European expert opinion on the management of invasive candidiasis in adults

2011

Item does not contain fulltext This report discusses the present status of antifungal therapy and treatment options for candidaemia, considered by experts in the field in Europe. A conference of 26 experts from 13 European countries was held to discuss strategies for the treatment and prevention of invasive candidiasis, with the aim of providing a review on optimal management strategies. Published and unpublished comparative trials on antifungal therapy were analysed and discussed. Commonly asked questions about the management of candidaemia were selected, and possible responses to these questions were discussed. Panellists were then asked to respond to each question by using a touchpad ans…

Invasive mycoses and compromised host Translational research [N4i 2]AdultMicrobiology (medical)medicine.medical_specialtyAntifungal Agentsmedicine.medical_treatmentPlacebo-controlled studyMEDLINEInvasive mycoses and compromised host Infection and autoimmunity [N4i 2]MicrobiologyMedicineHumanscandidaemiaCandidiasis InvasiveguidelinesIntensive care medicineWatchful Waitingtherapybusiness.industryTreatment optionsPathogenesis and modulation of inflammation Infection and autoimmunity [N4i 1]General MedicineInvasive candidiasisComparative trialAntibiotic Prophylaxismedicine.diseaseOptimal managementEuropeIntensive Care UnitsInfectious DiseasesconsensusExpert opinioncandidabusinessWatchful waitingClinical Microbiology and Infection
researchProduct

UC-USP collaborative exercise on photobiomodulation therapy in neurological orofacial disturbances.

2020

Background Neurosensory peripheral disorders are one of the most common risks associated with iatrogenic and/or post-traumatic injuries. It is often related to disability. Photobiomodulation therapy (PBMT) is a nonsurgical and safe procedure which can accelerate and improve the regeneration of injured biological tissue. This study aims to analyze the impact of PBMT, in the quality of life and impairment of individuals with orofacial neurological peripheral disturbance. Material and methods A retrospective analysis in the database of the dental traumatology clinic of the Hospital Centre of the University of Coimbra/Faculty of Medicine of the University of Coimbra was performed.5 out of 50 in…

Light therapymedicine.medical_specialtyOral Medicine and Pathologybusiness.industrymedicine.medical_treatmentResearchMEDLINETraumatologyPlacebo:CIENCIAS MÉDICAS [UNESCO]PeripheralQuality of lifeUNESCO::CIENCIAS MÉDICASmedicinePhysical therapyAnxietymedicine.symptombusinessGeneral DentistryDepression (differential diagnoses)Journal of clinical and experimental dentistry
researchProduct

Clinical efficacy of a bleaching enzyme-based toothpaste. A double-blind controlled clinical trial.

2015

Abstract Objectives To assess the efficacy of a bleaching enzyme-based toothpaste. Material and methods A randomized clinical trial was carried out, comprising 48 participants with teeth exhibiting color A3 or higher according to the Vita Classical guide. One-half of the sample received the bleaching enzyme-based toothpaste (White Kin ® ), while the other received placebo toothpaste. Both products were supplied in identical containers and had the same composition except for the active components. The teeth color was measured with a spectrophotometer. The patients were instructed to brush their teeth three times a day during 3 min with the assigned product, during 12 weeks. The color measure…

LightnessAdultMalebusiness.product_categoryAdolescentDentistryCarbamide PeroxidePlaceboOral hygienelaw.invention03 medical and health sciencesYoung Adult0302 clinical medicineRandomized controlled trialDouble-Blind MethodlawStatistical significanceTooth BleachingMedicineHumansUrea030212 general & internal medicineLactoperoxidaseColorimetryTooth Bleaching AgentsGeneral DentistryTooth Bleaching AgentsToothpastebusiness.industry030206 dentistryMiddle AgedPeroxidesTreatment OutcomeSpectrophotometryColorimetryFemalebusinessToothpastesJournal of dentistry
researchProduct

The effect of orally administered probiotic Lactobacillus reuteri -containing tablets in peri-implant mucositis: a double-blind randomized controlled…

2015

Background and Objectives Probiotics create a biofilm and protect the oral tissues against the action of periodontal pathogenic bacteria. The aim of this study was to evaluate the effects of the oral probiotic Lactobacillus reuteri Prodentis upon the peri-implant health of edentulous patients with dental implants and peri-implant mucositis, establishing comparisons vs implants without peri-implant disease. Material and Methods A double-blind, placebo-controlled, prospective cross-over study was made. The patients were all edentulous and were divided into two groups, (A) no peri-implant disease, and (B) peri-implant mucositis affecting one or more implants. Patients with peri-implantitis wer…

Limosilactobacillus reuteriMaleMucositismedicine.medical_specialtyPeri-implant mucositisDentistryPlaceboGastroenterologylaw.inventionPlacebosProbioticDouble-Blind MethodRandomized controlled triallawInternal medicinemedicineMucositisHumansProspective StudiesProspective cohort studyAgedCross-Over Studiesbiologybusiness.industryProbioticsMiddle Agedmedicine.diseasebiology.organism_classificationCrossover studyLactobacillus reuteriDental ImplantationTreatment OutcomeCytokinesPeriodonticsFemalebusinessTabletsJournal of Periodontal Research
researchProduct

Introduction: Using Placebo Research to Explore Belief and Healing in Late Antiquity

2021

Abstract This special issue explores belief and healing in Late Antiquity, through insight and terminology developed in modern placebo research. My introduction outlines the history of placebo research and its use in historical studies of medicine and healing. It has helped historians pose new questions to their sources and discuss them in light of modern medical research. Most studies analyse various descriptions or records of symptoms or diagnoses, but some researchers also extend their work to include social or anthropological studies of healing. Summarizing insights from such efforts in medical research and the history of medicine, I propose a selection of questions and perspectives fro…

Literaturebusiness.industrymedia_common.quotation_subjectPlaceboMagic (paranormal)03 medical and health sciencesLate Antiquity0302 clinical medicine030212 general & internal medicineClassicsPsychologybusiness030217 neurology & neurosurgerymedia_commonTrends in Classics
researchProduct

Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia

2012

Eltrombopag is an oral thrombopoietin-receptor agonist. This study evaluated the efficacy of eltrombopag for increasing platelet counts and reducing the need for platelet transfusions in patients with thrombocytopenia and chronic liver disease who are undergoing an elective invasive procedure.We randomly assigned 292 patients with chronic liver disease of diverse causes and platelet counts of less than 50,000 per cubic millimeter to receive eltrombopag, at a dose of 75 mg daily, or placebo for 14 days before a planned elective invasive procedure that was performed within 5 days after the last dose. The primary end point was the avoidance of a platelet transfusion before, during, and up to 7…

Liver CirrhosisMaleCirrhosisChronic liver diseaseBenzoateslaw.inventionchemistry.chemical_compoundRandomized controlled triallawReceptorsClinical endpoint80 and overMedicineCIRRHOSISAged 80 and overBenzoic AcidsGeneral MedicineCHRONIC LIVER DISEASEMiddle AgedHydrazinesThrombopoietinElective Surgical ProceduresAnesthesiaFemaleElective Surgical ProcedureReceptors ThrombopoietinAdultAdolescentEltrombopagELTROMBOPAGHemorrhagePlatelet TransfusionPlaceboYoung AdultDouble-Blind MethodElectiveSurgical Procedures ElectiveHumansAgedTHROMBOCYTOPENIA; ELTROMBOPAG; CIRRHOSIS; CHRONIC LIVER DISEASESurgical Proceduresbusiness.industryPlatelet CountTHROMBOCYTOPENIAcirrhosisSettore MED/09 - MEDICINA INTERNAmedicine.diseaseThrombocytopeniaPlatelet transfusionchemistryChronic DiseasePyrazolesbusiness
researchProduct

Octreotide compared with placebo in a treatment strategy for early rebleeding in cirrhosis. A double blind, randomized pragmatic trial.

1998

beta-Blockers and sclerotherapy prevent long-term upper digestive rebleeding in cirrhosis but they seem ineffective for early rebleeding. We compared octreotide with a placebo for the prevention of early rebleeding in cirrhotic patients. After control of acute upper digestive bleeding, 262 consecutive cirrhotic patients were randomized to octreotide 100 microgram subcutaneously three times a day for 15 days (n = 131) or to the placebo (n = 131), in a double blind pragmatic trial in which beta-blockers and/or sclerotherapy were allowed together with the experimental treatment. Separate randomization and analysis were performed according to whether patients were eligible for beta-blockers and…

Liver CirrhosisMalemedicine.medical_specialtyRandomizationmedicine.medical_treatmentAdrenergic beta-AntagonistsOctreotidePlaceboOctreotideHemostaticsPlacebosDouble-Blind MethodMelenaRecurrenceSclerotherapymedicineSclerotherapyHumansHepatologybusiness.industryHematemesisLength of StayMiddle AgedSurgeryClinical trialSurvival RateTreatment OutcomeChemoprophylaxisFemaleComplicationVaricesbusinessGastrointestinal Hemorrhagemedicine.drugHepatology (Baltimore, Md.)
researchProduct

Anti-fibrotic therapy: lost in translation?

2012

While preclinical development of potential anti-fibrotics is far advanced, with numerous pharmacological targets and promising agents, almost none has entered clinical validation. Reasons are manifold, including the usually slow progression of liver fibrosis, requiring high numbers of well-stratified patients undergoing long-term treatment when conventional liver biopsy based parameters or hard liver-related endpoints are used. Importantly, there is a notorious lack of sensitive and specific surrogate markers or imaging technologies for liver fibrosis progression or regression that would permit a rapid clinical screening for potential anti-fibrotics. Nonetheless, in view of an urgent need f…

Liver Cirrhosismedicine.medical_specialtyCirrhosisPlacebo-controlled studyAutoimmune hepatitisChronic liver diseaseGastroenterologyPrimary sclerosing cholangitisTranslational Research BiomedicalPrimary biliary cirrhosisFibrosisInternal medicinemedicineAnimalsHumansIntensive care medicineHepatologymedicine.diagnostic_testbusiness.industryPatient Selectionmedicine.diseaseMagnetic Resonance ImagingDisease Models AnimalLiver biopsybusinessBiomarkersJournal of hepatology
researchProduct